Sitemap | Contact Us

Daiichi-Sankyo

Home > About Welchol

About Welchol

Sign Up for Updates

Be notified about site updates, educational opportunities, and more.

Sign Up Now

About Welchol

For patients with type 2 diabetes and/or primary hyperlipidemia who need additional A1C and LDL-C reductions, adding Welchol™ (colesevelam HCl):

  • Achieves additional mean A1C reductions of up to 0.8% when added to preexisting antidiabetic (AD) monotherapy
  • Achieves nearly 50% total mean LDL-C reduction when added to atorvastatin 10 mg1
  • Effective without entering the bloodstream
  • Provides an established safety record in the treatment of primary hyperlipidemia
  • Preferred formulary status on most managed care plans2

Efficacy

Learn more about the efficacy of Welchol in type 2 diabetes and in primary hyperlipidemia.

Dosage & Administration

Learn about the dosing and administration of Welchol.

Welchol is indicated as an adjunct to diet and exercise to:

  • Reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor
  • Improve glycemic control in adults with type 2 diabetes mellitus

References

1. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001;158:407-16.

2. Data on file. Daiichi-Sankyo, Inc., Parsippany, NJ.

Effective Therapy

For patients with type 2 diabetes, adding Welchol can provide additional A1C reductions.

See A1C Data

IMPORTANT INFORMATION ABOUT WELCHOL

INDICATIONS

Welchol is indicated as an adjunct to diet and exercise to:

  • Reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor
  • Improve glycemic control in adults with type 2 diabetes mellitus

Important Limitations of Use

  • Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis
  • Welchol has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones
  • Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias

CONTRAINDICATIONS

Welchol is contraindicated in individuals with bowel obstruction, those with serum triglyceride (TG) concentrations of >500 mg/dL, or with a history of hypertriglyceridemia-induced pancreatitis.

WARNINGS AND PRECAUTIONS

Welchol can increase serum TG concentrations particularly when used in combination with sulfonylureas or insulin. Caution should be exercised when treating patients with TG levels >300 mg/dL. Welchol may decrease the absorption of fat-soluble vitamins A, D, E, and K. Patients on vitamin supplements should take their vitamins at least 4 hours prior to Welchol. Caution should be exercised when treating patients with a susceptibility to vitamin K or fat soluble vitamin deficiencies. Caution should also be exercised when treating patients with gastroparesis, gastrointestinal motility disorders, major gastrointestinal tract surgery, and when treating patients with dysphagia and swallowing disorders. Welchol reduces gastrointestinal absorption of some drugs. Drugs with a known interaction with colesevelam (glyburide, levothyroxine, and oral contraceptives [ethinyl estradiol, norethindrone]) should be administered at least 4 hours prior to Welchol. Drugs that have not been tested for interaction with colesevelam, especially those with a narrow therapeutic index, should also be administered at least 4 hours prior to Welchol. Alternatively, the physician should monitor drug levels of the co-administered drug.

ADVERSE REACTIONS

Primary Hyperlipidemia: In clinical trials, the adverse reactions observed in placebo – regardless of investigator assessment of causality were constipation (11.0% vs. 7.0%), dyspepsia (8.3% vs. 3.5%), nausea (4.2% vs. 3.9%), accidental injury (3.7% vs. 2.7%), asthenia (3.6% vs. 1.9%), pharyngitis (3.2% vs. 1.9%), flu syndrome (3.2% vs. 3.1%), rhinitis (3.2% vs. 3.1%) and myalgia (2.1% vs. 0.4%). Type 2 Diabetes: In clinical trials, the adverse reactions observed in placebo – regardless of investigator assessment of causality were constipation (8.7% vs. 2.0%), nasopharyngitis (4.1% vs. 3.6%), dyspepsia (3.9% vs. 1.4%), hypoglycemia (3.0% vs. 2.3%), nausea (3.0% vs. 1.4%) and hypertension (2.8% vs. 1.6%). Post-marketing experience: Due to the voluntary nature of these reports it is not possible to reliably estimate frequency or establish a causal relationship. Increased seizure activity or decreased phenytoin levels have been reported in patients receiving phenytoin concomitantly with Welchol. Reduced International Normalized Ratio (INR) has been reported in patients receiving warfarin concomitantly with Welchol.

PREGNANCY

Welchol is Pregnancy Category B.

The photos on this site depict models, not actual patients or healthcare professionals.

This information is intended for U.S. healthcare professionals only.
© 2008 Daiichi Sankyo, Inc.